Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Half Yearly Report

28th Mar 2012 12:34

RNS Number : 2692A
ABCAM Plc
28 March 2012
 



For Immediate Release

28 March 2012

 

 

ABCAM PLC

("Abcam" or "the Company")

 

Notification of Interim Results

 

Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, announces that its Interim Report for the six months ended 31 December 2011 has been posted to shareholders and is available at the Company's investor relations website, www.abcamplc.com.

 

 

For further information please contact:

 

Abcam

+ 44 (0) 1223 696000

Jonathan Milner, Chief Executive Officer

Jeff Iliffe, Chief Financial Officer

Numis Securities

+ 44 (0) 20 7260 1000

Michael Meade / Nick Westlake - Nominated Adviser

James Black - Corporate Broking

Buchanan Communications

+ 44 (0) 20 7466 5000

Mark Court / Jessica Fontaine

 

 

Notes for editors:

 

About Abcam plc

Abcam is a producer and distributor of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level, which is essential in understanding health and disease.

Headquartered in Cambridge (UK), Abcam has subsidiary offices in Bristol (UK), Cambridge, MA (USA), Eugene, OR (USA), Tokyo (Japan) and Hong Kong (China), allowing it to serve a global customer base in over 85 countries. Abcam employs over 340 staff across its six operating companies.

Abcam now has an online catalogue of over 88,000 products sourced from over 300 suppliers. The catalogue includes a growing range of non-primary antibody products such as secondaries, proteins, peptides, lysates, immunoassays and other kits. Products are available for life science research and distributed to academic and commercial users. A highly developed eCommerce platform, which includes regional websites for the Chinese and Japanese markets, allows customers to access up-to-date and detailed technical product data sheets at the Company's website www.abcam.com.

Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company's vision is to be the leading provider of protein research tools globally.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DOCZMGZFMRRGZZM

Related Shares:

ABC.L
FTSE 100 Latest
Value8,809.74
Change53.53